Tag: Cancer: Bladder
Extended Lymphadenectomy Fails to Improve Survival in Bladder Cancer
Extended lymphadenectomy does not improve disease-free, overall survival and is linked to more adverse events
Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer
Improved disease-free survival seen among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery
Socioeconomic Disparities Impact Immunotherapy Use in Urologic Cancers
Disparities seen based on income, education, and insurance status for both advanced kidney, bladder cancer
Survival Up With Enfortumab Vedotin + Pembrolizumab in Urothelial Cancer
Significantly longer progression-free and overall survival seen in patients with previously untreated locally advanced or metastatic urothelial carcinoma
Erdafitinib Improves Survival in Metastatic Urothelial Cancer With FGFR Mutation
Longer median overall survival and progression-free survival seen with erdafitinib versus chemotherapy
Selenium Not Linked to Recurrence of Non-Muscle-Invasive Bladder Cancer
Vitamin E supplementation is associated with increased risk for recurrence; neither influenced progression, overall survival
Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
Clinical complete response of 43 percent seen for those with muscle-invasive bladder cancer receiving neoadjuvant gemcitabine, cisplatin, plus nivolumab
Urine-Based DNA Methylation Test Can Detect Bladder Cancer
PENK methylation test has high sensitivity and specificity for detecting bladder cancer in patients with hematuria
Exposure to Agent Orange Linked to Risk of Bladder Cancer
Small, but significantly increased, risk for male Vietnam vets; increased risk seen among veterans younger than the median age
Bladder Cancer Treatment May Lower Risk for Alzheimer and Related Dementias
Greater effect seen for patients aged 70 years and older at time of bacillus Calmette-Guerin vaccination
